• The Consolidated Revenue from Operations for the quarter and nine months for FY26 stood at ₹ 342.42 Cr. and ₹ 1050.09 Cr. respectively. The Revenue of the above periods grew by 15.0% and 16.3% respectively, on Y-o-Y basis.
  • PAT [1] for the quarter and nine months FY26 was ₹ 55.56 Cr. and ₹ 154.08 Cr. respectively.
  • The PAT [1] of the above periods grew by 23.7% and 30.7% respectively, on Y-o-Y basis.

Ahmedabad : CORONA Remedies Limited, today announced the unaudited results for the third quarter and nine months ended December 31, 2025, as approved by its Board of Directors.

Q3 FY26 Financial Highlights:

Particulars (₹ in Cr.)Q3 FY26Nine Months FY26
Revenue from Operations342.421,050.09
EBITDA83.16231.42
EBITDA Margin24.3%22.0%
Profit After Tax [1]55.56154.08
Profit After Tax Margin [1]16.2%14.7%

Nine Months FY26 Key Financial Metrics:

ParticularsNine Months FY26
RoE[1] [2]31.1%
RoCE[1] [2]48.0%
OCF to EBITDA86.3%
Net Working Capital Days18 Days

[1] Excludes onetime statutory impact of New Labour Code ₹ 19.10 Cr. (Post Tax ₹14.29 Cr.)

[2] Annualised

Commenting on the results, Mr. Nirav K. Mehta, Managing Director and CEO, CORONA Remedies Limited, said:

“We are delighted to report a strong financial performance in Q3 and 9MFY26. Revenues for Q3 and 9MFY26 grew by 15.0% and 16.3% respectively on a Y-o-Y basis, outperforming the IPM growth. Adjusted Profit after tax for Q3 and 9MFY26 grew by 23.7% and 30.7% respectively on a Y-o-Y basis while maintaining healthy return ratios. We have been consistently delivering on our guided

We have transformed our aspiration of growing Revenues by 15% and PAT by 20% into successful achievement. Our revenues & PAT has grown as per our aspiration in the last 3 quarters and are optimistic of maintaining similar trajectory going forward.

Our strong performance reflects the consistency of our strategy, disciplined execution and deep focus on our core therapeutic segments. By strengthening our field force, expanding our brand portfolio and maintaining a sharp focus on specialists’ prescriptions, we have continued to outperform the market while building a sustainable platform for long-term growth. I would also like to thank the entire team at CORONA and our stakeholders for their continued support and faith in our business.”